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1. Introduction 
Confirmation of a clinical diagnosis of a heritable disorder usually involves the analysis of 
the coding exons of a gene, plus surrounding intronic sequences. Variants that are identified 
using this strategy can be classed as either disease-causing or non-pathogenic 
polymorphisms. The variants comprise point mutations, micro insertions and deletions 
(indels), and copy number changes. 
The detection of small variants (such as substitutions and indels) can be identified using a 
number of techniques including SSCP (Orita et al., 1989), DHPLC (Yu et al., 2006) and high-
resolution melt-curve analysis (Garritano et al., 2009; Montgomery et al., 2010; Ngyyen-
Dumont et al., 2009). These techniques can de difficult to optimise and can result in both 
false negative and false positive results. The accepted gold standard of mutation detection, 
however, is dideoxy-based sequencing. This is the most direct approach and can be the most 
sensitive of all techniques. However, it is also the most expensive option and can be the 
most time-consuming due to bottle-necks arising from designing appropriate primers, the 
analysis of subsequent sequence data, and the interrogation of data to filter out sequence 
variants that are not disease-causing. Within our laboratory, we experienced difficulties in 
three principal areas: standardising the primer design; objectively evaluating sequence data 
that can be performed in an automated manner thereby addressing the bottle-neck of trace 
sequence evaluation; and responding to the increasing need for in-depth analysis of 
sequence variants to inform referring physicians as to the clinical significance of the data. 
To resolve the above issues, we developed a system that addressed each of these areas. The 
first involved designing primers that are assessed for unique amplification of targeted 
genomic regions using standard conditions. The aim here was not to tailor PCR conditions 
to a primer pair, but to force all primer designs to satisfy only one condition. The ancillary 
design feature of this module was to tail all primers such that all amplicons could be 
sequenced bi-directionally using only two primers (the “tail” sequences), thereby avoiding 
sequencing using amplicon-specific primers. The second area involved the wholesale 
adoption of Variant ReporterTM software (Applied Biosystems Ltd) for the automated 
analysis of all sequence data. This decision led to a significant initial investment in time to 
establish appropriate reference sequence projects for each of the genes analysed by our 
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laboratory. But critically, these templates can be applied to any gene of interest and have 
been successfully implemented within our laboratory to produce quality trace data for use 
in a diagnostic testing. The third area comprised a streamlined approach to bioinformatic 
analysis of sequence variants, which has replaced ad hoc and superficial analysis in order to 
support our reports to referring physicians. This aspect of our work remains a constant 
challenge and should be viewed as work-in-progress as more web-based bioinformatic tools 
become available. 
2. Materials and methods 
2.1 DNA purification 
DNA was extracted from peripheral blood (taken in EDTA) using the Gentra Puregene 
DNA Extraction kit (Qiagen Ltd). If blood spots/Guthrie spots were used then DNA was 
extracted using the Qiagen Miniblood kit (Qiagen Ltd). 
2.2 PCR conditions 
PCR was performed using the following reagents in a 25µl reaction volume: 50 ng genomic 
DNA, Faststart buffer (Roche Applied Science), 2 mM MgCl2, forward and reverse primers 
at 0.8µM each, 0.4mM dNTPs (GE Healthcare Ltd), 1 unit Fast Start Taq DNA polymerase 
(Roche Applied Science) and +/- 5µl GC-rich solution (Roche Applied Science); most PCRs 
did not require GC-rich solution. 
The reaction conditions for all PCRs were: 95°C for 4 minutes followed by 35 cycles of 94°C 
for 45 seconds, 60°C for 30seconds and 72°C for 30seconds, with a final extension of 72°C for 
10 minutes. 
Primers designed using the Primer3 programme of the UCSC genome browser were tested 
first under the conditions above. If PCR failed, a second set of primers was designed using 
Primer3 and manual adjustment of the region to be amplified, or the alternative software 
design tool, FastPCR (see later). 
5 µl of PCR product was purified using ExoSAP-IT® (USB) and subjected to bidirectional 
sequence analysis using Big-Dye Terminator v3.0 (Applied Biosystems), and 2.5ng per 100bp 
of amplified product. 20µl sequenced products were purified using Clean-Seq (Agencourt). 
15ul of purified sequenced product was then subjected to capillary electrophoresis using a 
3130xls Applied Biosystems Genetic Analyser with a 50cm capillary array. 
2.3 Sequence analysis 
All trace sequences were analysed with KB™ Basecaller v1.4. Most of the sequence analysis 
parameters were set using the default values defined in Variant ReporterTM (Applied 
Biosystems). The mixed base threshold was set at the default of 25%. After base calling, the 
5’ and 3’ ends were trimmed to remove sequence until fewer than 4 bases in a window of 20 
had Quality values of less than 20; the resulting sequence is termed the clear range or 
contiguous read length (CRL). Traces were filtered with a minimum Trimmed Read Length 
(TRL) of fewer than 50 base pairs; the TRL is sequence that remains after trimming using the 
defined quality values. Traces were filtered with a Median Under Peak (PUP) of less than 4 
(this is the median value within the clear range of the ratio of the signal of the highest 
secondary peak to the signal of the main called base). Traces were filtered if the expected 
TRL was less than 50% of the trace length providing a minimum trace score of 35. This is the 
average quality value of bases in the clear range which equates to a base-call error rate of 
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0.031%. A reference negative control DNA sample was sequenced for each gene in order for 
the algorithm to work. 
3. Results 
3.1 Primer design 
Our main aim was to produce high-quality sequence traces spanning all coding exons plus 
flanking intronic sequence of any gene of interest. We arbitrarily chose to examine 20 base 
pairs of flanking intronic sequence in order to detect splice acceptor and donor variants. The 
priority for the primer design process was to produce primers that allowed for PCR 
amplification under standard buffer conditions using only one cycling protocol. Placing the 
emphasis on primer design rather than PCR optimisation was advantageous in reducing 
both technical time and reagent costs. Figure 1 shows the primer design workflow. 
 
 Identify UCSC gene based on RefSeq gene of interest using
http://genome.ucsc.edu/1
Connect to Exonprimer from UCSC-
http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html2
-use default settings for automated primer design
SNP check primers using
http://ngrl.man.ac.uk/SNPCheck/SNPCheck.html3
SNP identified 






Perform Primer3 search using mispriming library and 
default settings.
http://frodo.wi.mit.edu/4
Alternative primers sourced using FastPCR
http://www.biocenter.helsinki.fi/bi/Programs/
download.htm.5






Variant Reporter analysis  
 
Fig. 1. Primer design workflow 
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The first objective involves the identification of the mRNA sequence of each gene of interest. 
This is achieved by interrogating the public UCSC genome browser page 
http://genome.ucsc.edu/ (Figure 2A) and identifying an appropriate RefSeq accession 
number (Figure 2B), and the relevant UCSC accession number (Figure 2C). This website also 
provides a direct link to ExonPrimer for design of primers specific to this mRNA sequence 
(http://ihg.helmholtz-muenchen.de/ihg/ExonPrimer.html); see Figure 2. ExonPrimer 
provides exon and amplicon size and creates additional primer sets as alternatives. We use 
the ExonPrimer default parameters as this achieves our objective of designing primers 








Fig. 2. ExonPrimer design 
Following primer design, all primers are checked for single nucleotide polymorphisms 
(SNPs) using the software tool available from the National Genetic Reference Laboratory, 
Manchester, UK (https://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck.htm). This is a 
bioinformatics program which allows for batch checking of primers for SNPs. It uses the 
current build of the human genome to identify the position in the sequence where the 
primers bind. The current release of dbSNP is used to detect any known SNPs at the primer 
binding sites. Primers that do not show SNPs are tailed with universal M13 sequences and 
used in PCR +/- GC-rich solution and our standard amplification conditions. Figure 3 
shows a schematic of the tailed primers flanking two exons of a hypothetical gene (panel A), 
and the amplification products achieved after the PCR amplification of 11 unique exons (+/- 
genomic DNA). 
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Fig. 3. Schematic of amplicons and gel electrophoresis of amplicons 
If a SNP is detected then a second set of primers is designed using Primer3 (Rozen & 
Skaletsky et al., 2000; http://frodo.wi.mit.edu/primer3/) in which we use the default 
settings; however, we highlight the human mis-priming library to avoid designing primers 
to regions of interspersed repeats. If the need arises, alternative primers are also designed 
using the freely available FastPCR programme 
(http://www.biocenter.helsinki.fi/bi/Programs/download.html). This programme 
includes various bioinformatics tools that can be used for the design of a variety of PCR 
applications. Following identification of primers using the default settings, we select primer 
pairs with annealing temperatures close to 600C and amplicon lengths of approximately 
400bp for optimal electrophoresis through our 50cm capillary array. Again, SNP checks of 
these primers are performed and all successful primers are tailed with universal M13 
forward or reverse sequences. Unlike Exonprimer, these tools do not have an integrated 
search for cross-complementation to other areas of the genome. The UCSC website can be 
used for this purpose by selecting the in silico PCR option. This screens the primer pairs 
against the human genome and provides details of sequences that lie between the primers, 
and includes the primer pair. It also includes chromosome location and hence can be used to 
identify primer pairs which amplify homologous regions of the genome. The above design-
on-demand pipeline has enabled us to design and implement primers for screening a 
number of disease-associated genes; we are in the process of writing a programme that will 
perform all of the above steps automatically. 
www.intechopen.com





 Reference sequence design 
Our chosen software for the analysis of sequence traces is Variant ReporterTM developed by 
Applied Biosystems. This software tool uses advanced algorithms and quality metrics to 
automate the detection of variants and streamline the data analysis process, thereby greatly 
reducing the time required to analyse trace sequences. Additional features also allow for 
quality trace scoring over defined regions. 
The first step in setting up sequence analysis using Variant ReporterTM is to produce a 
reference sequence for each gene, as shown in figure 4.  
 
mRNA reference sequence modified to 
incorporate 250bp of flanking intronic sequence
Tailor the modified mRNA sequence to a genbank 
file with defined exons and 20bp of flanking 
intronic sequence
Upload the tailored genbank file into Variant 
Reporter and annotate the exons/introns as 
Regions of Interest (ROI)
Primers designed using 10bp 5' and 3' of intronic 
sequence defined above to create amplicons 
replicating the ROI’s
Variant Reporter analysis performed using specific 
quality parameters 




Fig. 4. General workflow in setting up a project in Variant ReporterTM 
In our experience, the Variant ReporterTM programme has difficulty accepting large genomic 
reference sequences, therefore we reduce the reference sequence to a size which can be 
accommodated by the software. In our laboratory the reference sequences used are those of the 
mRNA of the gene of interest, which can be downloaded from the UCSC genome browser. This 
approach is in accordance with current international guidelines, which specify the reporting of 
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changes in relation to the mRNA accession number as specified by the Human Genome 
Variation Society (HGVS) Guidelines 
(http://www.genomic.unimelb.edu.au/mdi/mutnomen/). We modify each mRNA reference 
sequence using the UCSC genome browser to include enough intronic sequence to cover the 
maximum length of every amplicon we intend to sequence. This involves amending the mRNA 
reference sequence of the gene of interest to include 250bp of 5’ and 3’intronic sequence. 
We then adapt the modified mRNA reference file to a tailored Genbank reference file which 
includes the defined exons and 20bp of flanking introns to create a “pseudo Genbank” file. 
Once the file has been imported into Variant ReporterTM it can be annotated to define the 
regions of interest (ROIs).  
In the case of small genes, the workflow for constructing appropriate files for Variant 
ReporterTM is described below. 
1. Identify the mRNA reference sequence for the targeted gene 
The first stage is to identify the current mRNA reference sequence for the gene of interest in 
the UCSC genome browser. This is done by entering the UCSC genome browser and 
clicking on the ‘Genomes’ link and entering the gene name or RefSeq accession number in 
the search term box (Figure 5A). On the next page, click on the highlighted RefSeq (Figure 






Fig. 5. Retrieving genomic sequence of gene of interest 
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2. Modify the mRNA reference sequence to incorporate 250bp of flanking intronic 
sequence. 
The Sequence Retrieval Region Option is used to set the regions to 250bp (or to the user 
specification; Figure 6A). The Sequence Formatting Options allows for exon formatting in 
upper case and intronic regions in lower case (Figure 6B). This formatting is extremely 
useful for downstream visualisation of these regions in Variant ReporterTM. The resulting 
sequence can be pasted into an appropriate program (such as notepad) in which all the 
RefSeq annotations are removed and the file is saved as .txt file. The lengths of each exon 
can be calculated easily using the word count character option. At this stage the modified 
mRNA sequence can be uploaded into Variant ReporterTM. The exons and flanking intronic 





Fig. 6. Retrieving exon sequences with flanking 250bp of intron sequence 
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3. Annotate exons and introns as regions of interest (ROI) 
The ‘define reference’ link of Variant ReporterTM is used to import the ‘modified reference 
sequence’ from step 2. At this point the user can choose to delete redundant reference 
sequences using the ‘delete layer’ option from the ‘Layers’ tab. The Variant ReporterTM 
reference sequence can now be annotated according to the user specifications using the 
‘Create/Edit ROI’ option from the ROI tab. The ROI start for each exon is specified on the 
‘Cumulative Exon start co-ordinates section’ of an exon formatting spreadsheet. 
4. Design primers using 10bp 5' and 3' of intronic sequence to create amplicons 
replicating the ROI. 
A main feature of Variant ReporterTM is that it provides quality statistics based on the 
amplicon, not the region of interest (ROI). Therefore, we adopted an in silico approach to 
make the ROIs coincident with the amplicons. This approach involved using the first 10 
bases of each 5’ intronic region as the forward primer, and reverse complemented the last 10 
bases of the corresponding 3’ intron to create the reverse primer. A freely available reverse-
complement web-site (http://www.bioinformatics.org/SMS/rev_comp.html) can be used 
for this purpose. The primers can be easily identified by highlighting the corresponding 






Fig. 7. Creation of regions of interest to replicate amplicons 
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The reverse-complement web browser is then used to reverse complement the 3’ intron. An 
example of the .txt format that can be used to upload the primers into Variant ReporterTM is 
shown in Figure 7B. Note that the primer pair name will correspond to the amplicon name 
as it appears in Variant ReporterTM. Once the primer sequences have been imported, the 
amplicons are automatically created and correspond to the exon plus flanking 20bp intron 
(Figure 7C). Nucleotide numbering of the coding regions starts with nucleotide 1 as A of the 
major initiation codon. Intronic sequences are referred to as -n or +n where –1 denotes the 
invariant G of the AG splice acceptor site, and +1 indicates the invariant G of the GT splice 
donor site, in accordance with HGVS nomenclature. 
5. Establishing specific quality parameters in Variant ReporterTM 
The user can select default Analysis Parameters or customize their personal settings. We 
choose to set a minimum trace score of 35 equating to an average base-call error rate of 
0.031%. These can be set using the Analysis Parameters tab. 
The above workflow has been used to establish sequencing projects for a large number of 






Adrenoleukodystrophy ABCD1 NM_000033.2 1-6 
Gastric Cancer (E-Cadherin) CDH1 NM_004360.2 1-16 
Maturity Onset of Diabetes in the 
Young (MODY) type 2 
GCK NM_000162.3 1-10 
MODY3 HNF-1α NM_000545.4 1-10 
Non-insulin dependent diabetes 
mellitus (NIDM) type I 
HNF-4α NM_000457.3 1-10 
Non ketotic hyperglycinaemia GLDC NM_000170.2 1-25 
Holocarboxylase synthetase 
deficiency 
HLCS NM_000411.4 4-12 
Rett Syndrome MECP2 NM_004992.3 1-4 
SDHB NM_003000.2 1-9 
SDHC NM_003001.3 1-6 
Paragangliomas and 
Pheochromocytoma 
SDHD NM_003002.1 1-4 
Myoclonus dystonia SGCE NM_001099400.1 1-11 
Von Hippel-Lindau syndrome VHL NM_000551.2 1-3 
Long QT Syndrome (LQT) type 1 KCNQ1 NM_000218.2 1-16 
LQT2 HERG NM_000238.2 1-15 
LQT3 SCN5A NM_198056.2 2-28 
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LQT5 KCNE1 NM_000219.3 3 
LQT6 KCNE2 NM_172201.1 2 
LQT7 KCNJ2 NM_000891.2 2 
Myoclonus dystonia SGCE NM_003919.2 1-10 
Familial adenomatous polyposis APC NM_000038.4 2-16 
Multiple Endocrine Neoplasia 
(MEN) type 2A/2B 
RET NM_020630.4 10-16 
Table 1. Genes for which Variant ReporterTM projects have been established 
3.3 Bioinformatic analysis 
Comparison of the sequence traces from a patient with those of a negative control individual 
in Variant ReporterTM results in the identification of sequence variants that differ from the 
relevant RefSeq sequences. The final step for a diagnostic laboratory is to use a method of 
“filtering” these variants to identify those that are benign (likely to be, but not necessarily, 
silent mutations at the amino acid level), and so provide a much more limited set of variants 
that may or may not be disease-causing. Our routine work flow is shown in Figure 8, which 
accesses a number of web-based analysis tools to interrogate the data in a formal manner. 
The reader can refer to many recent publications that highlight the work of others in 
classifying sequence variants in the context of their disease association (Abkevich et al., 
2004; Sullivan et al., 2006; Lee et al., 2008; Arnold et al., 2009). 
The work flow can be divided into a series of modules, which are summarised below: 
1. Convert the locations of sequence variants in HGVS nomenclature 
(http://www.hgvs.org/mutnomen/) into predicted consequences on translation using 
the Mutalyzer web site (http://www.mutalyzer.nl/2.0/).  
2. Interrogate sequence variants against SNP databases to determine if they represent 
known polymorphisms with associated rs identifiers. These variants are present in the 
general population and so would likely be non-pathogenic. 
3. Interrogate sequence variants against disease-associated databases such as the Leiden 
Open Variation Database (LOVD; http://www.lovd.nl/2.0/) and the HGVS locus 
specific mutation databases (http://www.hgvs.org/dblist/glsdb.html). 
4. Predict the functional consequences of predicted amino acid changes on protein 
function using evolutionary sequence conservation and physico-chemical 
considerations provided by web-based tools such as SIFT 
(http://sift.jcvi.org/www/SIFT_seq_submit2.html) and Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/); Ng & Henikoff 2003; Tavtigian et al., 2008; 
Adzhubei et al., 2010; Flanagan et al., 2010. 
5. Predict the effect of sequence variants on splicing (Walker et al., 2010). 
The outcome of the above workflow provides laboratory staff with information that either 
strongly supports the conclusion that a sequence variant is a (benign) polymorphism, a 
disease-causing mutation, or of unknown clinical significance. The latter creates dilemmas 
for the laboratory, but usually leads to continuing family studies to determine if the variant 
co-segregates with the disease, or in vitro/modelling studies that necessitate research-based 
laboratory involvement. 
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Fig. 8. Bioinformatic workflow 
4. Discussion 
The integration of the processes described above has allowed us to design a sequencing 
strategy suited to obtaining high-throughput quality controlled sequence data. To date, we 
have evaluated over 1000 sequence traces with the end point being high-quality data 
passing defined quality thresholds set in Variant ReporterTM. 
The first stage of the sequencing pipeline involved primer design. Here, our main emphasis 
was to create a structured template requiring minimal intervention from the operator. A 
tiered strategy consisting of the UCSC browser, Primer3 and FastPCR tools enables the 
selection of several primer pairs which can be M13-tailed and tested under standard 
conditions. By focusing initially on primer design rather than reaction optimisation we have 
reduced costs in technical time as well as reagents. In addition, M13 tailing of final-stage 
primers also decreases both operator time and error and opens the process to automation. In 
combination with the use of the SNP software tool and UCSC in silico PCR, this has enabled 
the rapid design of specific primers. 
We chose to use primers which covered at least 20 bases of flanking introns in order to 
detect splice variants. Other laboratories may choose to design primers at different sites to 
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include deeper intronic variants. However, there is a lack of international best practice 
guidelines defining the length of intronic sequence necessary for diagnostic reporting. Until 
this is resolved, each laboratory will continue to sequence differing flanking lengths 
affecting the detection of deeper intronic variants that potentially have pathogenic 
properties. As recommended by the Clinical Molecular Genetics Society (CMGS; 
http://cmgsweb.shared.hosting.zen.co.uk/BPGs/Best_Practice_Guidelines.htm, retired 
publication), it is good practice for the diagnostic laboratory to specify the length of flanking 
intron that is sequenced in order for the clinician to gain a clear understanding of the 
genomic regions that have been assessed for each patient. 
The second stage of the sequencing pipeline involved establishing Variant ReporterTM 
reference sequences and downstream analysis. This was initially run in parallel to our 
established sequencing analysis system, a more manual-orientated software tool which 
compared test and control sequences. Here, it was necessary for the user to scan the 
sequences as not all changes were automatically detected by the software. These variants 
were not genotyped by the software, therefore the user had to manually call the variant. In 
addition, the software did not provide quality scoring of the sequence data.  
Initial problems were encountered as Variant ReporterTM was unable to accept large 
genomic reference sequences. Therefore we chose to create a modified reference sequence to 
a size that could be accommodated by the software. This approach involved using the UCSC 
genome browser to incorporate 250 bp of flanking intronic sequence into the selected mRNA 
sequence. In turn, this modified sequence could be annotated as a Genbank file and 
uploaded into Variant ReporterTM to create a reference file that included highlighted regions 
of interest. This process alleviated the time-consuming step of creating the reference 
sequence manually in Variant ReporterTM. 
At the point of analysis it is necessary to incorporate a reference sample in the project in 
addition to the test sample. We routinely use a pre-sequenced negative control to compare 
with patient samples. Without the use of this reference sample we have found that Variant 
ReporterTM fails to detect pre-identified variants. As described by Applied Biosystems, this 
is due to the algorithm requiring a second sample for trace comparison. 
Once optimisation of the reference file and project parameters was completed, we 
analysed over 1000 sequence traces in parallel using Variant ReporterTM and our 
conventional method. All substitutions identified by our conventional method were 
successfully detected and genotyped automatically by Variant ReporterTM. In addition, 
the heterozygosity/homozygosity of each variant matched. All data passed our quality 
threshold set in Variant ReporterTM of a minimum trace score of 35 equating to an average 
base-call error rate of 0.031% (as now specified on all diagnostic reports produced from 
our laboratory). Our new system has reduced the time taken to analyse samples to 
roughly 10% of the original time (a reduction from 8 hours for a full multi-gene screen to 1 
hour). 
A major inconsistency which we have identified, however, is the failure of Variant 
ReporterTM to identify and correctly name indels. In order to circumvent this problem we 
manually evaluate all samples not reaching 100% trimmed read length (TRL) as identified 
through the trace quality review using the procedures above. The % TRL is the length of the 
sequence that remains after trimming, divided by the amplicon length. A % TRL falling 
beneath the 100% threshold as identified through the trace score feature can be used to 
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indicate a potential insertion or deletion. Our in-house protocol for these samples now 
involves scanning of these traces in the variant review window. 
Once an insertion/deletion mutation has been detected visually we manually score the 
result. This approach also addresses the problem of inconsistencies in genotyping data in 
that Variant ReporterTM uses a different nomenclature system from the current HGVS 
international guidelines for diagnostic laboratories 
(http://cmgsweb.shared.hosting.zen.co.uk/BPGs/Best_Practice_Guidelines.htm). 
Both of these issues are currently being assessed by Applied Biosystems. 
In our experience the Variant ReporterTM default trace score of 25 allows for trailing C 
shoulders indicative of a sub-optimal array. By increasing this score to 35, the threshold is 
raised sufficiently to exclude low-quality sequence data. At present there is no universal 
consensus on minimal quality settings that should be used by the genetic community. 
Until there is, each laboratory will continue to use its own standards of quality scoring 
which will result in different rates of false negatives for each laboratory. We feel that 
international guidelines are needed to address this concern within the diagnostic 
laboratory. 
While we were implementing enhanced primer design and the assessment of sequence 
traces using Variant ReporterTM, our bioinformatic analysis strategy also required attention. 
The approach described here is evolutionary as more programmes become available on-line 
to predict the biological significance of sequence variants. In this respect, it should be noted 
that similar challenges in biological interpretation are occurring in the field of whole 
genome molecular karyotyping (Marquis-Nicholson et al., 2010). The construction of 
international databases comprising well-curated data from diagnostic laboratories (Cotton et 
al., 2008) should improve our understanding of variants and improve the genetic analysis of 
individuals and their families with heritable disorders. 
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